SCHEMBL2170407

SCHEMBL2170407

CS(=O)(=O)OC1CCNC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14603804 1.00
SCHEMBL10679088 1.00
SCHEMBL10599712 0.89 L3MBTL1 (0.35)
SCHEMBL29134621 0.82 HTT (0.31)
SCHEMBL29475802 0.77 MEN1 (0.35)
SCHEMBL18231654 0.74
SCHEMBL12683411 0.74
SCHEMBL12683410 0.74
SCHEMBL31145894 0.73
SCHEMBL1027078 0.73 CRBN (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114989140-B Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer 卡佩拉医疗公司 2025-03-25 CN disclosed
US-20250092028-A1 BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER CAPELLA THERAPEUTICS, INC. 2025-03-20 US disclosed
CN-114940673-B Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer 卡佩拉医疗公司 2025-03-18 CN disclosed
CN-116997548-A HTT modulators for the treatment of huntington's disease CHDI基金会股份有限公司 2023-11-03 CN disclosed
US-11787788-B2 Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof CAPELLA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11787788-B2 Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof CAPELLA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11787788-B2 Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof CAPELLA THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20230271938-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES CAPELLA THERAPEUTICS, INC. 2023-08-31 US disclosed
US-20230271938-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES CAPELLA THERAPEUTICS, INC. 2023-08-31 US disclosed
US-20230159564-A1 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers iTeos Belgium SA (BE) 2023-05-25 US disclosed
WO-2015135461-A1 SUBSTITUTED DIHYDROBENZOFURAN-PIPERIDINE-KETONE DERIVATIVE, PREPARATION AND USE THEREOF 四川海思科制药有限公司 2015-09-17 WO disclosed
EP-2731940-B1 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-08-19 EP disclosed
US-20150126513-A1 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 US disclosed
WO-2014198808-A1 TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES ASCENEURON SA (CH) 2014-12-18 WO disclosed
EP-2813505-A1 Tetraaza-cyclopenta[a]indenyl derivatives Asceneuron SA (CH) 2014-12-17 EP disclosed
EP-2731940-A1 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS Novartis AG (CH) 2014-05-21 EP disclosed
WO-2013008217-A1 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2013-01-17 WO disclosed
EP-2346870-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS Merck & Cie (CH) 2011-07-27 EP disclosed
WO-2010040854-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS MERCK EPROVA AG (CH) 2010-04-15 WO disclosed
EP-0257602-A1 (5R,6S,8R)-6-(1-hydroxyethyl)-2-(3R-pyrolidin-2-one-3-yl-)thiopenem-3-carboxylic acid SCHERING CORPORATION (US) 1988-03-02 EP disclosed